RNA amidates and thioamidates for RNAi
The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3′→P5′ phosphoramidate (NP) and ribo-N3′→P5′ thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
1. An isolated small interfering RNA (siRNA) comprising an oligonucleotide of 19 to 25 nucleotides in length that is complementary to a target nucleic acid sequence, wherein:
all of the nucleosides of the oligonucleotide are of the formula:
wherein each R 1 is independently chosen from fluorine and OR 2 , R 2 is chosen from hydrogen and lower alkyl, and B is chosen from purines, pyrimidines, and analogs thereof; and
at least one internucleoside linkage in the oligonucleotide is a ribo-N3′→P5′ phosphoramidate (NP) linkage; and
wherein the small interfering RNA is selected from a single-stranded antisense form, or a double-stranded form comprising both sense and antisense strands wherein at least one strand comprises the oligonucleotide.
2. The small interfering RNA according to claim 1 , wherein all of the internucleoside linkages in the oligonucleotide are chosen from ribo-N3′→P5′ phosphoramidate (NP) and ribo thiophosphoramidate (NPS) linkages.
3. The small interfering RNA according to claim 1 , wherein the RNA further comprises at least one covalently conjugated lipid moiety.
4. The small interfering RNA according to claim 3 , wherein the at least one lipid moiety is covalently conjugated to the 5′ or 3′ terminus of the RNA, and the at least one lipid moiety is chosen from fatty acids, sterols and hydrocarbons.
5. The small interfering RNA according to claim 3 , comprising the structure:
O-( x -L) n
wherein
O is the oligonucleotide;
L is a lipid moiety;
x is an optional linker; and
n is an integer ranging from 1 to 5, wherein if n>1, each additional (x-L) component may be, independently, the same or different.
6. The small interfering RNA according to claim 5 , wherein L is a lipid chosen from substituted and unsubstituted fatty acids and sterols; or wherein L is chosen from substituted and unsubstituted hydrocarbons.
7. The small interfering RNA according to claim 6 , wherein L is chosen from fatty acids substituted with at least one fluorine; or wherein L is chosen from hydrocarbons substituted with at least one fluorine.
8. The small interfering RNA according to claim 5 , wherein at least 60% of the nucleobases in the oligonucleotide are ribonucleobases.
9. A method for effecting the post-transcriptional silencing of at least one gene, comprising administering to a mammal in need of such post-transcriptional silencing at least one small interfering RNA according to claim 1 .
10. The method of claim 9 , wherein the small interfering RNA further comprises at least one covalently conjugated lipid moiety.
11. The method of claim 9 , wherein the at least one gene encodes at least one mRNA chosen from cellular mRNAs and viral mRNAs; or wherein the at least one gene is an oncogene; or wherein the at least one gene is a viral gene.
12. A method for effecting the post-transcriptional silencing of at least one gene, comprising administering to a mammal in need of such post-transcriptional silencing at least one small interfering RNA according to claim 5 .
13. The method according to claim 12 , wherein the at least one gene encodes at least one mRNA chosen from cellular mRNAs and viral mRNAs; or wherein the at least one gene is an oncogene; or wherein the at least one gene is a viral gene.
14. The small interfering RNA according to claim 1 , wherein said small interfering RNA is in single-stranded form, and is effective to inhibit the expression of an endogenous mammalian target RNA sequence.
15. The single-stranded small interfering RNA according to claim 14 , wherein the small interfering RNA further comprises at least one covalently conjugated lipid moiety.
16. The single-stranded small interfering RNA according to claim 14 , wherein the target RNA sequence is encoded by a human gene.
17. The small interfering RNA according to claim 1 , wherein said small interfering RNA is in double-stranded form, and is effective to inhibit the expression of an endogenous mammalian target RNA sequence.
18. The double-stranded small interfering RNA according to claim 17 , wherein the target RNA sequence is encoded by a human gene.
19. The double-stranded small interfering RNA according to claim 17 , wherein the RNA further comprises at least one covalently conjugated lipid moiety.
20. A small interfering RNA as recited in claim 1 wherein said target nucleic acid sequence is a human immunodeficiency virus (HIV) gene, such that said siRNA modulates expression of said HIV gene.
21. The small interfering RNA according to claim 20 , wherein the small interfering RNA further comprises at least one covalently conjugated lipid moiety.
22. A small interfering RNA as recited in claim 1 wherein said target nucleic acid sequence is a beta site APP-cleaving enzyme (BACE) gene, such that said siRNA modulates expression of said BACE gene.
23. The small interfering RNA according to claim 22 , wherein the small interfering RNA further comprises at least one covalently conjugated lipid moiety.
24. A small interfering RNA as recited in claim 1 wherein said target nucleic acid sequence is an EGFR gene, such that said siRNA modulates expression of said EGFR gene.
25. The small interfering RNA according to claim 24 , wherein the small interfering RNA further comprises at least one covalently conjugated lipid moiety.
26. A small interfering RNA as recited in claim 1 wherein said target nucleic acid sequence encodes K-Ras, such that said siRNA modulates expression of said K-Ras.
27. The small interfering RNA according to claim 26 , wherein the small interfering RNA further comprises at least one covalently conjugated lipid moiety.
28. A small interfering RNA as recited in claim 1 wherein said target nucleic acid sequence is a prostaglandin D2 receptor (PTGDR) gene, such that said siRNA modulates expression of said PTGDR gene.
29. The small interfering RNA according to claim 28 , wherein the small interfering RNA further comprises at least one covalently conjugated lipid moiety.
30. A small interfering RNA as recited in claim 1 wherein said target nucleic acid sequence is an ADORA1 gene, such that said siRNA modulates expression of said ADORA1 gene.
31. The small interfering RNA according to claim 30 , wherein the small interfering RNA further comprises at least one covalently conjugated lipid moiety.
32. The small interfering RNA according to claim 1 , wherein at least one nucleoside comprises the formula
wherein R 1 is selected from fluorine and OR 2 wherein R 2 is methyl.
33. The small interfering RNA according to claim 2 , wherein all of the internucleoside linkages are ribo-N3′→P5′ phosphoramidate (NP) linkages.
34. The small interfering RNA according to claim 33 , wherein at least one nucleoside comprises the formula
wherein R 1 is selected from fluorine and OR 2 wherein R 2 is methyl.
35. The small interfering RNA according to claim 1 , wherein at least one of the internucleoside linkages is a ribo-N3′→P5′ thiophosphoramidate (NPS) linkage.
36. The small interfering RNA according to claim 34 , wherein at least one nucleoside comprises the formula
wherein R 1 is selected from fluorine and OR 2 wherein R 2 is methyl.
37. The small interfering RNA according to claim 35 , wherein all of the internucleoside linkages in the oligonucleotide are chosen from ribo-N3′→P5′ phosphoramidate (NP) and ribo N3′→P5′ thiophosphoramidate (NPS) linkages.
38. The small interfering RNA according to claim 37 , wherein at least one nucleoside comprises the formula
wherein R 1 is selected from fluorine and OR 2 wherein R 2 is methyl.